Negative results of humoral immunity after anti-SARS-COV-2 vaccination in patient with advanced ovarian cancer treated with maintenance immunotherapy and targeted therapy: a clinical case and а literature review
Автор: Rumyantsev A.A.
Журнал: Злокачественные опухоли @malignanttumors
Рубрика: Клиническое наблюдение
Статья в выпуске: 1 т.11, 2021 года.
Бесплатный доступ
Gam-COVID-Vac (Sputnik V, Gamaleya Research Institute of Epidemiology and Microbiology of Ministry of Health of Russian Federation) is an adenovirus viral vector vaccine for COVID-19 which became the very first vaccine against SARS-CoV-2 registered in Russia and worldwide. The vaccine efficacy and safety in cancer patients is unknown. We present a clinical case of the absence of post-vaccination immunity after the use of Gam-COVID-Vac in a patient with advanced ovarian cancer treated with maintenance targeted and immunotherapy and discuss it in the light of the available evidence base on the effectiveness of other anti-SARS CoV-2 vaccines in cancer patients.
Covid-19, sars-cov-2, спутник v
Короткий адрес: https://sciup.org/140256694
IDR: 140256694 | DOI: 10.18027/2224-5057-2021-11-1-5-8